EMEA-000716-PIP01-09-M03

Table of contents

Key facts

Invented name
Mayzent
Active substance
Siponimod (hemifumarate)
Therapeutic area
Neurology
Decision number
P/0014/2021
PIP number
EMEA-000716-PIP01-09-M03
Pharmaceutical form(s)
Film-coated tablet
Condition(s) / indication(s)
Treatment of multiple sclerosis
Route(s) of administration
Oral use
Contact for public enquiries
Novartis Europharm Limited
United Kingdom
E-mail: paediatric.enquiries@novartis.com
Tel.: +41 613241111
Decision type
PM: decision on the application for modification of an agreed PIP

Decision

Related content

How useful was this page?

Add your rating